# OS Therapies Incorporated (OSTX)

> Source: Nexqual · https://nexqual.com/OSTX · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, OS Therapies Incorporated (OSTX), nexqual.com/OSTX" · informational, not investment advice.

**Price:** USD 1.41 (+1.44% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 1.39 · day 1.38–1.44 · 52w 1.15–2.25 · market cap $66.0M · ASE

## Key facts
- Analysts: Buy (mean 1.75 on a 1–5 scale) (4 analysts), mean target USD 8.5 (range 6–13).
- Total return with dividends: 1Y -23.8% vs S&P 500 +18.1%; 5Y -64.8% vs S&P 500 +85.1%.
- Next earnings: 2026-11-16, EPS estimate USD -0.12, revenue estimate $0K.

## Analysts
Consensus Buy (mean 1.75 on a 1–5 scale), 4 analysts; mean target USD 8.5 (low 6, high 13).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-09 | Roth Capital | Initiated | Buy | $7 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2024-07-29) |
|---|---|---|
| Total return | -23.8% | -64.8% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -23.9% | -37.6% |
| Volatility (annualized) | 73.7% | 94.6% |
| Max drawdown | -42.9% (Dec 2025→Feb 2026) | -77.1% (Dec 2024→Feb 2026) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/OSTX · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt